ArticleVector borne and zoonotic diseases (Larchmont, N.Y.)2014
Criteria for identifying and evaluating candidate sites for open-field trials of genetically engineered mosquitoes.
Article in Vector borne and zoonotic diseases (Larchmont, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Pooled it
- Considerations for first field trials of low-threshold gene drive for malaria vector control.Malaria journal · 2024Review
- Acceptability of emergent Aedes aegypti vector control methods in Ponce, Puerto Rico: A qualitative assessment.PLOS global public health · 2024Article
- Selection of sites for field trials of genetically engineered mosquitoes with gene drive.Evolutionary applications · 2021Article
- Sterile Insect Technique: Successful Suppression of anInsects · 2021Article
- Article
- Community acceptance of yeast interfering RNA larvicide technology for control of Aedes mosquitoes in Trinidad.PloS one · 2020Article
- Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus.PLoS neglected tropical diseases · 2018Article
- Pathway to Deployment of Gene Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of Malaria in Sub-Saharan Africa: Recommendations of a Scientific Working GroupThe American journal of tropical medicine and hygiene · 2018Article
- Mosquito control practices and perceptions: An analysis of economic stakeholders during the Zika epidemic in Belize, Central America.PloS one · 2018Article
- Gene drives in our future: challenges of and opportunities for using a self-sustaining technology in pest and vector management.BMC proceedings · 2018Review
- Studies of Transgenic Mosquitoes in Disease-Endemic Countries: Preparation of Containment Facilities.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2018Article
- Teilhard de Chardin's oeuvre within an ongoing discussion of a gene drive release for public health reasons.Life sciences, society and policy · 2017Review
- Population modification of Anopheline species to control malaria transmission.Pathogens and global health · 2017Review
- Anopheline Reproductive Biology: Impacts on Vectorial Capacity and Potential Avenues for Malaria Control.Cold Spring Harbor perspectives in medicine · 2017Review
- Rules of the road for insect gene drive research and testing.Nature biotechnology · 2017Article
- Meeting Report: Translational Considerations of Novel Vector Management Approaches.PLoS neglected tropical diseases · 2016Article
- Control of Mosquito-Borne Infectious Diseases: Sex and Gene Drive.Trends in parasitology · 2016Review
- Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Engaging scientists: An online survey exploring the experience of innovative biotechnological approaches to controlling vector-borne diseases.Parasites & vectors · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent laboratory successes in the development of genetically engineered mosquitoes for controlling pathogen transmission have fostered the need for standardized procedures for advancing the technical achievements to practical tools. It is incumbent in many cases for the same scientists doing the in-laboratory discovery research to also take on the initial challenges of developing the pathway that will move the technologies to the field. One of these challenges is having a set of criteria for selecting collaborators and sites for efficacy and safety field trials that combine rigorous science with good ethical and legal practices. Specific site-selection criteria were developed in four categories-Scientific, Regulatory, Community Engagement, and Resources-in anticipation of open-field releases of a transgenic mosquito strain designed to suppress populations of the dengue vector mosquito, Aedes aegypti. The criteria are derived from previous published material, discussions, and personal experiences with the expectation of providing guidance to laboratory scientists for addressing the conceptual and operational considerations for identifying partner researchers and countries with whom to collaborate. These criteria are not intended to be prescriptive nor can they be applied to every circumstance where genetic approaches are proposed for deployment. However, we encourage those involved in the discovery phase of research to consider each criterion during project planning activities, and where appropriate, incorporate them into a "go/no-go" decision-making process for further development and testing of the technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.